EverImmune

Executive Summary

EverImmune is a French biotechnology company pioneering microbiome oncology through its proprietary live biotherapeutic products (LBPs), collectively known as Oncobax®. Founded in 2016 and headquartered in Villejuif, Paris region, the company focuses on developing oral adjuvants designed to modulate the gut microbiome and overcome resistance to immune checkpoint inhibitors (ICIs) in cancer patients. By targeting the gut-immune axis, EverImmune aims to enhance the efficacy of existing immunotherapies such as anti-PD-1/PD-L1 agents, addressing a significant unmet need where over 60% of patients fail to respond to ICIs. The company's approach builds on a growing body of evidence linking gut microbiota composition to immunotherapy outcomes, positioning it at the forefront of the microbiome-oncology field. EverImmune's lead candidate, Oncobax®, is entering early-stage clinical trials, with the company seeking to validate its safety and efficacy in combination with standard ICIs. As a private firm with limited disclosed funding history, EverImmune likely relies on venture capital and non-dilutive grants to advance its pipeline. The company faces typical early-stage risks, including clinical trial uncertainty and regulatory hurdles, but its innovative approach and strong scientific rationale provide a differentiated value proposition. Key upcoming milestones include initial clinical data readouts, potential Series A financing, and strategic partnerships with larger pharmaceutical companies interested in microbiome-based cancer therapies.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical data readout for Oncobax® in combination with anti-PD-1 therapy60% success
• Q4 2026Series A or Series B financing round70% success
• Q1 2027Licensing or co-development partnership with a major pharma company40% success